U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H26N4O3
Molecular Weight 394.4668
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PF-03716556

SMILES

CN(CCO)C(=O)C1=CN2C=C(C)N=C2C(N[C@@H]3CCOC4=CC=CC(C)=C34)=C1

InChI

InChIKey=YBHKBMJREUZHOV-QGZVFWFLSA-N
InChI=1S/C22H26N4O3/c1-14-5-4-6-19-20(14)17(7-10-29-19)24-18-11-16(22(28)25(3)8-9-27)13-26-12-15(2)23-21(18)26/h4-6,11-13,17,24,27H,7-10H2,1-3H3/t17-/m1/s1

HIDE SMILES / InChI
Molecular Formula C22H26N4O3
Molecular Weight 394.4668
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

PF-03716556 is a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease. PF-03716556 inhibits the porcine, canine, and human recombinant gastric H+,K+-ATPase in a competitive manner without any biologically relevant activity against other tested receptors, ion channels, and enzymes, including the Na+,K+-ATPase. PF-03716556 inhibits gastric acid secretion in a dose-dependent manner in Ghosh-Schild rats and Heidenhain pouch dogs, producing full efficacy on treatment day 1. PF-03716556 is used for the treatment of gastroesophageal reflux disease.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
 6.0 null [pIC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Basic research
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease.
2009-02
Patents

Patents

US8946158
1

Sample Use Guides

In Vivo Use Guide
Rats: Intraduodenal administration of PF-03716556 inhibited gastric acid secretion in a dose-dependent manner over concentrations ranging from 1 to 10 mg/kg. Complete inhibition was observed at 10 mg/kg PF-03716556. Heidenhain Pouch Dogs:Dose-dependent inhibition of gastric acid secretion was observed following oral administration of PF-03716556 at doses ranging from 0.3 to 3 mg/kg; complete inhibition was observed at 3 mg/kg
Route of Administration: Other
In Vitro Use Guide
In porcine ion-tight membrane vesicles, PF-03716556 inhibited H,K-ATPase activity in a concentration-dependent manner, with a pIC50 value of 7.095 at pH 7.4
Substance Class Chemical
Created
by admin
on Mon Mar 31 22:45:26 GMT 2025
Edited
by admin
on Mon Mar 31 22:45:26 GMT 2025
Record UNII
701L6668UD
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IMIDAZO(1,2-A)PYRIDINE-6-CARBOXAMIDE, 8-(((4R)-3,4-DIHYDRO-5-METHYL-2H-1-BENZOPYRAN-4-YL)AMINO)-N-(2-HYDROXYETHYL)-N,2-DIMETHYL-
Preferred Name English
PF-03716556
Common Name English
Code System Code Type Description
PUBCHEM
25134521
Created by admin on Mon Mar 31 22:45:26 GMT 2025 , Edited by admin on Mon Mar 31 22:45:26 GMT 2025
PRIMARY
CAS
928774-43-0
Created by admin on Mon Mar 31 22:45:26 GMT 2025 , Edited by admin on Mon Mar 31 22:45:26 GMT 2025
PRIMARY
EPA CompTox
DTXSID10648811
Created by admin on Mon Mar 31 22:45:26 GMT 2025 , Edited by admin on Mon Mar 31 22:45:26 GMT 2025
PRIMARY
FDA UNII
701L6668UD
Created by admin on Mon Mar 31 22:45:26 GMT 2025 , Edited by admin on Mon Mar 31 22:45:26 GMT 2025
PRIMARY
Related Record Type Details
Structure of PF-03716556
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966